NAD+ Boosters for Longevity: What the Clinical Evidence Actually Shows
As NAD+ precursors like NR and NMN dominate the longevity market, a review of 2026 clinical data separates proven human healthspan benefits from mouse-model hype.
By Factlen Editorial Team
Longevity Researchers 40%Clinical Skeptics 40%Regulatory Bodies 20%
- Longevity Researchers
- Focus on the profound cellular benefits seen in animal models and advocate for early adoption of precursors to maintain healthspan.
- Clinical Skeptics
- Demand rigorous Phase 3 human clinical trials before making broad recommendations, noting that mouse biology often fails to translate to humans.
- Regulatory Bodies
- Prioritize consumer safety and strict definitions between dietary supplements and investigational new drugs.
What's not represented
- · Supplement Manufacturers
- · Consumer Biohackers
Why this matters
Millions of consumers are spending heavily on longevity supplements based on animal studies. Understanding the actual human clinical data allows you to make evidence-based decisions about your healthspan, budget, and wellness routines.
More in health
See all 125 stories →Peptide Therapy
How Experimental Peptides Moved From Niche Biohacking to Mainstream Wellness
8 sources
Nutritional Psychiatry
The Evidence for Nutritional Psychiatry: How Diet Modifies Mental Health
7 sources
Sleep Science
How Temperature and Light Optimize Deep Sleep and Brain Health
7 sources
CAR-T Therapy
CAR-T Cell Therapy Puts Severe Lupus Into Remission in UK Trial
7 sources
Stay informed
Every angle. Every day.
Get health stories with full source coverage and perspective breakdowns delivered to your inbox.